Complicated Pain Management in a CYP450 2D6 Poor Metabolizer

@article{Foster2007ComplicatedPM,
  title={Complicated Pain Management in a CYP450 2D6 Poor Metabolizer},
  author={Adriana Foster and Elizabeth Mobley and Zixuan Wang},
  journal={Pain Practice},
  year={2007},
  volume={7}
}
▪ Abstract:  We describe the case of a patient with significant adverse effects from posttraumatic analgesic therapy with opioid analgesics who was found by microarray analysis to have a CYP2D6 genotype predictive of a poor metabolizer phenotype. In addition to her poor tolerance and limited response to opioid analgesics, she developed further discomfort when the antiemetic promethazine was administered to treat her gastrointestinal adverse effects. In our discussion we review the literature… 
View on Wiley
ncbi.nlm.nih.gov
76 Citations
Background Citations
23
Results Citations
3

76 Citations

IN RESPONSE TO DR. AHDIEH
TLDR
It is proposed that another option for those patients who are poor CYP2D6 metabolizers might be oxymorphone, which does not undergo any form of CYP450 metabolism but is instead metabolized primarily via glucuronidation, which might reduce the potential complications associated with opioid therapy in CYP1D6 poor metabolizers, and might also have a lower interaction potential when administered concurrently with other CYP 450-dependent drugs.
REGARDING CYP450 2D6 POOR METABOLIZERS
  • H. Ahdieh
  • Medicine, Biology
    Pain practice : the official journal of World Institute of Pain
  • 2008
TLDR
It is proposed that another option for those patients who are poor CYP2D6 metabolizers might be oxymorphone, which does not undergo any form of CYP450 metabolism but is instead metabolized primarily via glucuronidation, which might reduce the potential complications associated with opioid therapy in CYP1D6 poor metabolizers, and might also have a lower interaction potential when administered concurrently with other CYP 450-dependent drugs.
The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Towards personalized opioid dosing: A concise overview of CYP polymorphisms
TLDR
Patients who have genotype polymorphisms in these enzymes are phenotypically (clinically) poor, intermediate, extensive, or ultra-rapid metabolizers, affecting how rapidly or to what extent an individual patient metabolizes opioids.
Pharmacokinetic, pharmacodynamic and pharmacogenetic aspects of oxycodone treatment in cancer pain
TLDR
YP2D6 genotypes did not influence pain control, the adverse symptoms nausea and sedation or the risk for cognitive failure in patients treated with oxycodone for cancer pain, and had no pharmacodynamic consequence.
Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study.
TLDR
This pilot study supports the need for further research in this topic, and CYP genotyping of individual patients prior to receiving opiate analgesics to inform precision-guided decisions, improve therapeutic efficacy, and, most importantly, increase patient well-being and safety.
Variable response to opioid treatment: any genetic predictors within sight?
TLDR
There is no clear evidence that genetic markers can be used to predict opioid efficacy or adverse effects in palliative care patients, which reflects the general lack of studies performed in the context of palliatives care, the lack of sufficiently scaled studies and the Lack of international standards for the assessment of subjective symptoms.
A review of the role of genetic testing in pain medicine.
TLDR
Genetic testing may explain and predict many of the clinical responses seen with opioids and adjuvant medications, and may help the clinician identify those patients at genetic risk of opioid misuse and addiction.
Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism
TLDR
It is opine that pharmacogenetic testing, especially for CYP2D6 with considerations of phenoconversion due to concomitant drug administration, should be appraised to improve oxycodone efficacy.
The pharmacogenomics of pain management: prospects for personalized medicine
TLDR
This narrative review will attempt to cover the current understanding of the pharmacogenomics of pain, examining common genes affecting metabolism of analgesic medications, their distribution throughout the body, and end organ effects.
...
...

References

SHOWING 1-10 OF 38 REFERENCES
Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects
TLDR
This study confirms that codeine O-demethylation depends on CYP2D6; it shows that the 6-glucuronidation of morphine is independent of CYP6; and it supports the theory that the analgesic effect of codeine depends on its O- Demethylation; and indicates that this is probably also the case for the adverse effects.
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.
TLDR
A 33-year-old woman who experienced severe pain in the epigastrium after codeine intake was phenotyped and genotyped as an ultrarapid metabolizer with high capacity to metabolize codeine to morphine.
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation
Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients
TLDR
Data from these studies demonstrate that the pharmacokinetics and pharmacodynamics of intravenous famotidine appear to be similar in both children over the age of 1 year and adults, and support a starting paediatric dosage of 0.5 mg/kg every 8 to 12 hours.
Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.
TLDR
The data suggest only a small role of hydromorphone in eliciting abuse-related responses to oral hydrocodone, and quinidine had no consistent effect on their responses, even thoughQuinidine abolished the pre-existing metabolic differences in hydrom orphone production, as measured in urine.
The Role of Opioids in Cancer Pain Management
TLDR
The role of opioids in the treatment of cancer pain is described, including a brief overview of cancerPain syndromes, essential aspects of opioid therapy, opioid pharmacology, opioid rotation, properties of the individual opioids, and management of common side effects of opioids.
Antidepressants for neuropathic pain.
TLDR
This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine.
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.
TLDR
Pharmacokinetic drug-drug interactions with morphine, hydromorphone, and oxymorphone are reviewed in this column and suggest that inhibition or induction of UGT enzymes could alter morphine and its metabolite levels.
...
...